Indivior Pharmaceuticals (INDV) Total Liabilities (2021 - 2026)

Indivior Pharmaceuticals' Total Liabilities history runs 6 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Total Liabilities fell 19.22% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 19.22% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 21.31% from the prior year.
• Total Liabilities improved to $1.3 billion in Q1 2026 per INDV's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $1.9 billion in Q4 2023 and bottomed at $1.3 billion in Q4 2025.
• The 5-year median for Total Liabilities is $1.7 billion (2024), against an average of $1.6 billion.
• Across the five-year window, Total Liabilities gained 13.04% in 2023 and retreated 21.31% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $1.7 billion in 2022, then climbed by 13.04% to $1.9 billion in 2023, then declined by 14.93% to $1.7 billion in 2024, then slipped by 21.31% to $1.3 billion in 2025, then climbed by 3.15% to $1.3 billion in 2026.
• Per Business Quant, the three latest INDV Total Liabilities figures stand at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.6 billion (Q3 2025).